Strategic funding Zelira Therapeutics has recently secured substantial funding of US$33 million via an SPV deal, signaling strong investor confidence and available capital to advance clinical programs, partnerships, or expansion efforts in cannabinoid-based medicines.

Global expansion The company is actively expanding its market presence across the US, Australia, New Zealand, and Germany, creating multiple entry points for partnerships, distribution, and regional collaborations in high-potential cannabinoid markets.

Clinical pipeline With a multi-arm program like ZLT-L-007 and collaboration with Affinity Bio Partners on pivotal trials, Zelira demonstrates a capable R&D track record, offering opportunities for co-development deals, licensing, or strategic investments in later-stage assets.

Strategic leadership Appointments such as the addition of a non-executive director and ongoing governance enhancements indicate a readiness to scale, attract larger partners, and pursue structured commercial partnerships and governance-aligned collaborations.

R&D incentives Participation in government R&D tax incentive refunds improves net burn and funding efficiency, presenting a sales angle to potential customers or partners on cost-effective collaboration and potential co-funding arrangements.